A recent review published in the Journal of Oncology Practice explores how patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) view the use and timing of radioligand
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) in partnership with NETRF is proud to announce Dr. Carolin Kitzberger of TUM
The early results from a first-in-human clinical trial suggest that a novel copper-based PET imaging agent may deliver clearer and more comprehensive scans for people
Chimeric Therapeutics has reported that a neuroendocrine cancer patient in the Phase 1 clinical trial of CAR T cell therapy has experienced tumor shrinkage. In
By Anna Greene, PhD, NETRF Chief Scientific Officer NETRF-funded scientists uncover how oxygen levels shape tumor behavior and expose new treatment opportunities for pheochromocytomas and
By Anna Greene, PhD, NETRF Chief Scientific Officer Neuroendocrine cancers, such as neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), are rare and complex. That makes
Updated on October 31, 2025 Early clinical trial results show that AlphaMedix™ (212Pb-DOTAMTATE), an investigational targeted alpha therapy, achieved all of its main goals and
By Anne-Marie Green, Director of Digital Communications We recently spoke with Burt Rosen, who was diagnosed with both an advanced PNET (Pancreatic Neuroendocrine Tumor) and
This is your opportunity to be part of a global effort to improve neuroendocrine cancer care. The 2nd Survey of Challenges in Access to Diagnostics and Treatment for
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to transforming the future of neuroendocrine cancer care. As the world’s leading funder of neuroendocrine